98319-26-7 (非那雄胺,Finasteride)

非那雄胺;N-叔丁基-3-氧代-4-氮杂-5a-雄甾-1-烯-17b-甲酰胺;非那甾胺;非那甾胺(FTD);非那甾安;N-叔丁基-3-氧代-4-氮杂-5Α-雄甾-1-烯-17Β-甲酰胺;非那甾铵;N-(1,1-二甲基乙基)-3-羰基-4-氮杂-5Α-雄甾-1-烯-17Β-酰胺;* 非那甾胺;Finasteride 非那甾胺;FNS(非那雄胺);N-叔丁基-3-氧代-4-氮杂-5a-雄甾;zzstandard 品牌 非那雄胺对照品;达可隆;非那司提杂质;非那雄安;非那雄胺 USP标准品;非那雄胺 标准品;非那雄胺粉;非那雄胺中间体;非那甾胺（非那雄胺）;果胶;品质保证非那雄胺 非那雄胺原粉;非那甾胺 标准品;非那甾烷;N-(2-甲基-2-丙基)-3-氧代-4-氮杂-5α-雄甾-1-烯-17β-甲酰胺;

finasteride;n-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;proscar;(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;C23H36N2O2;FINASTERIDE, USP;Chibro-Proscar;Finasterida;Finasteridum;Finastid;Finpecia;MK906;MK-906;N-tert-Butyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamide;Propecia;Prostide;Finasteridum [INN-Latin];Finasterida [INN-Spanish];MK 906;MK 0906;N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-;N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-1;(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide;AKOS015894916;Prestwick0_000717;(5ALPHA,17BETA)-N-(1,1-DIMETHYLETHYL)-3-OXO-4-AZAANDROST-1-ENE-17-CARBOXAMIDE;17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one;Finasteride (Proscar);FINASTERIDE [VANDF];A845840;NCGC00016965-01;AB00513901-07;CPD000466304;SR-01000759414-6;NCGC00259057-01;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide;FINASTERIDE [EP MONOGRAPH];HMS2235L23;Finasteride, >=98% (HPLC), powder;BRD-K01095011-001-03-5;NSC-759318;HMS1570O15;FINASTERIDE (EP MONOGRAPH);Pro-Cure;(5?,17?)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide;BCPP000229;(4aR,6aS,7S,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;FINASTERIDE [EP IMPURITY];EX-A1951;D11AX10;L-652,931;FINASTERIDE [MART.];ENTADFI COMPONENT FINASTERIDE;FINASTERIDE (MART.);(17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one;Tox21_201506;N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide;FINASTERIDE COMPONENT OF ENTADFI;DB01216;FINASTERIDE [USAN];AB00513901;(4aR,6aS)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;DBEPLOCGEIEOCV-WSBQPABSSA-N;SR-01000759414;FINASTERIDE [JAN];Finasteride [USAN:USP:INN:BAN];4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5.alpha.,17.beta.)-;MK-0906;(5 alpha, 17 beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide;Prestwick1_000717;SR-01000759414-4;CAS-98319-26-7;(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-isobutyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;Q424167;57GNO57U7G;Z1501475008;(1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide;MFCD00869737;SMR000466304;N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide;KS-1058;SPBio_002854;NSC-757443;17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one;98319-26-7;(4AR,4BS,6AS,7S,9AS,9BS,11AR)-4A,6A-DIMETHYL-2-OXO-2,4A,4B,5,6,6A,7,8,9,9A,9B,10,11,11A-TETRADECAHYDRO-1H-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE;NS00010893;DTXCID50625;BCP0726000222;NSC 759318;Propecia (TN);MLS001424046;Tox21_302744;(4aR,4bS,6aS,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;HY-13635;FINASTERIDE (USP IMPURITY);BSPBio_000933;4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;FINASTERIDE [USP MONOGRAPH];Tox21_110717;4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-;Finasterida (INN-Spanish);(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide;CCRIS 7438;Finasteridum (INN-Latin);NSC757443;GTPL6818;DTXSID3020625;NSC 741485;Proscar (TN);(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-isobutyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;Finasteride;FINASTERIDE [ORANGE BOOK];FINASTERIDE [WHO-DD];1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-;UNII-57GNO57U7G;Finasteride (USAN:USP:INN:BAN);D00321;BRN 4269024;Finasteride, European Pharmacopoeia (EP) Reference Standard;BPBio1_001027;FINASTERIDE [USP IMPURITY];BRD-K01095011-001-15-9;BCP9000685;CCG-100937;HMS3714O15;BDBM50334788;G04CB01;NC00187;(4aR,6aS,11aR)-4a,6a-Dimethyl-2-oxo-hexadecahydro-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;HMS2097O15;BF164456;NSC-741485;Finasteride for peak identification, European Pharmacopoeia (EP) Reference Standard;s1197;(4aR,6aS,7S)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;140375-21-9;(R)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide;FINASTERIDE [MI];NCGC00256334-01;Prestwick3_000717;NCGC00093560-05;Prestwick2_000717;4a,6a,9a-Trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid (Finasteride);AB00513901_09;FINASTERIDE (EP IMPURITY);NSC741485;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide;Finasteride, United States Pharmacopeia (USP) Reference Standard;MLS000759404;Finasteride, British Pharmacopoeia (BP) Reference Standard;CS-1767;Finasteride (JAN/USP/INN);([1-PHENYL-METH-(E)-YLIDENE]-AMINO)-ACETICACIDETHYLESTER;AB00513901-08;HSDB 6793;HMS2051F09;Tox21_110717_1;YM-152;4-Azaandrost-1-ene-17-carboxamide,1-dimethylethyl)-3-oxo-, (5.alpha., 17.beta.)-;Urprosan;CHEBI:5062;SCHEMBL5509;MLS001165768;N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;Andozac;Finasteride, VETRANAL(TM), analytical standard;4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid tert-butylamide(Finasteride);CHEMBL710;Propeshia;FINASTERIDE (USP MONOGRAPH);HMS2090G22;FINASTERIDE [INN];

MFCD00869737

DBEPLOCGEIEOCV-WSBQPABSSA-N

1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

O=C([C@H]1CC[C@H]2[C@@H]3CC[C@@H]4[C@@](C=CC(N4)=O)(C)[C@H]3CC[C@@]21C)NC(C)(C)C

7438

2937290090

治疗前列腺增生，治疗男性型脱发药物。

以孕烯醇酮为原料.先和吡啶作用,再和甲醇钠反应得3-羟基-5-雄甾烯-17β-羧酸甲酯(Ⅲ).再和异丙醇铝在甲苯和环己酮中,回流.过滤,洗涤,干燥,减压浓缩.加入石油醚,于5℃搅拌,抽滤得氧化产物(Ⅳ),收率74.6%.该氧化产物和95%乙醇及10%氢氧化钾溶液,在氮气保护下回流.减压蒸去乙醇后,用6mol几盐酸调至Ph值约为3.抽滤,滤饼用水洗至中性,干燥得水解产物(V),收率96.4%.水解产物溶于叔丁醇中,搅拌下加入无水碳酸钠的水溶液,回流下滴加高碘酸钠和高锰酸钾的水溶液,加毕回流.冷却,过滤.滤液减压蒸去大部分叔丁醇后,冰浴下用6mol/L盐酸调至Ph值约为2.乙酸乙酯提取,提取液用饱和氯化钠洗,干燥.减压蒸干,乙酸乙酯重结晶得开环产物(Ⅵ),收率66%.在冰浴冷却下,往乙二醇中通入氨气,加入开环产物,缓慢升至180℃反应.冷却,加水,用6mol／I.盐酸调至Ph值约为...

4269024